Consequently, Tipifarnib was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with recurrent or metastatic HRAS mutant HNSCC and is currently being studied as a combination therapy with a PI3K inhibitor [109]. This evidence concerns the gene HRAS and head and neck squamous cell carcinoma.